title: Phyllodes tumors of the breast segregate in two groups according to genetic criteria.
abstract: Phyllodes tumors are rare fibroepithelial tumors of the breast. The pathologic grading of phyllodes tumors based on the aspect of the stromal component, is divided into 2 or 3 grades according to the system used. To determine whether genetic markers could be of use for improving the classification of phyllodes tumors and to provide a better knowledge of the genetic alterations in these tumors, we analyzed chromosomal changes detected by comparative genomic hybridization (CGH) in comparison with histological data, in a series of 30 cases. Recurrent chromosome imbalances were observed in 55, 91 and 100% of benign, borderline and malignant phyllodes tumors, respectively. The mean number of chromosome changes was one in benign, six in borderline, and six in malignant phyllodes tumors. Most frequent genetic imbalances were +1q (12/30), -13q (7/30), -6q (9/30), +5 (9/30) and -10p (8/30). Gains of 1q, present in only one of nine benign tumors, were found in 11/21 (51%) borderline or malignant tumors. Losses of 13q have 13q14.2 as smallest region of overlap, suggesting that the RB1 gene could be the target of deletions. Amplifications of 12q14, involving the MDM2 locus, and of 8p24, involving the MYC gene, were observed in one case each. Borderline and malignant phyllodes tumors could not be differentiated on the basis of their genomic imbalances (presence and number of chromosomal changes, presence of 1q gain and/or 13q loss). Conversely, benign tumors could be significantly differentiated from the group composed of borderline and malignant tumors (P<0.01). This study reveals two distinct patterns of genomic imbalance in phyllodes tumors: benign, with none or a few chromosome changes and malignant, with numerous recurrent chromosomal changes, in particular 1q gain and 13q loss. Helpful additional pathological criteria for differentiating the two genetic groups of phyllodes tumors are the nuclear size and the mitotic rate.
authors.affiliation: Département de Biologie des Tumeurs, Service de Pathologie, Institut Curie-Hôpital, Paris, France. marick.lae@curie.net
authors.forename: Marick
authors.initials: M
authors.lastname: Laé
authors.forename: Anne
authors.initials: A
authors.lastname: Vincent-Salomon
authors.forename: Alexia
authors.initials: A
authors.lastname: Savignoni
authors.forename: Isabelle
authors.initials: I
authors.lastname: Huon
authors.forename: Paul
authors.initials: P
authors.lastname: Fréneaux
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sigal-Zafrani
authors.forename: Alain
authors.initials: A
authors.lastname: Aurias
authors.forename: Xavier
authors.initials: X
authors.lastname: Sastre-Garau
authors.forename: Jérôme
authors.initials: J
authors.lastname: Couturier
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology; D002467:Cell Nucleus / Q000473:pathology; D002869:Chromosome Aberrations; D005260:Female; D005819:Genetic Markers; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D008938:Mitosis; D003557:Phyllodes Tumor / Q000145:classification / Q000235:genetics* / Q000473:pathology
chemical_list: D005819:Genetic Markers